

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation

Leona Dold¹, Philipp Lutz², Annkristin Heine², Tobias Weismüller², Christian Strassburg², and Ulrich Spengler²

¹Affiliation not available

²University Hospital Bonn

May 8, 2021

Abstract

Patients after liver transplantation have an increased risk to develop haematologic neoplasias. Information how to treat these patients in the context of immunosuppression is sparse. Here, we report two patients with polycythemia vera (PV) and myelofibrosis (MF) on ruxolitinib after liver transplantation.

Hosted file

Ruxolitinib_Clinical Case Reports.pdf available at <https://authorea.com/users/412650/articles/521262-ruxolitinib-for-treatment-of-polycythemia-vera-and-myelofibrosis-in-patients-after-liver-transplantation>